Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in Metastatic Breast Cancer
NCT00034918Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of vandetanib in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Objective Response Rate at 24 weeks. Started May 2002; status: completed.
02
Drugs
vandetanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00034918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034918.